1-6 of 6
Prafulla C. Gokhale
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Combination of Type I and Type II MET Tyrosine Kinase Inhibitors as Therapeutic Approach to Prevent Resistance

Magda Bahcall, Cloud P. Paweletz, Yanan Kuang, Luke J. Taus, Taebo Sim, Nam Doo Kim, Kshiti H. Dholakia, Christie J. Lau, Prafulla C. Gokhale, Pratik R. Chopade, Fangxin Hong, Zihan Wei, Jens Köhler, Paul T. Kirschmeier, Jiannan Guo, Sujuan Guo, Stephen Wang, Pasi A. Jänne
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2022) 21 (2): 322–335.
https://doi.org/10.1158/1535-7163.MCT-21-0344
Published: 08 February 2022
View article titled, Combination of Type I and Type II MET Tyrosine Kinase Inhibitors as Therapeutic Approach to Prevent Resistance
Open the PDF for Combination of Type I and Type II MET Tyrosine Kinase Inhibitors as Therapeutic Approach to Prevent Resistance in another window
Includes: Supplementary data
Journal Articles

Abstract P203: Milademetan is a potent, murine double minute 2 (MDM2) inhibitor, highly active in TP53 wild-type (p53WT) Merkel cell carcinoma (MCC) cell lines

Varsha Ananthapadmanabhan, Aine Knott, Kara M. Soroko, Prafulla C. Gokhale, Vijaya Tirunagaru, Robert Doebele, James A. DeCaprio
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2021) 20 (12_Supplement): P203.
https://doi.org/10.1158/1535-7163.TARG-21-P203
Published: 01 December 2021
View article titled, Abstract P203: Milademetan is a potent, murine double minute 2 (MDM2) inhibitor, highly active in TP53 wild-type (p53<sup>WT</sup>) Merkel cell carcinoma (MCC) cell lines
Journal Articles

ERK Inhibitor LY3214996-Based Treatment Strategies for RAS-Driven Lung Cancer

Jens Köhler, Yutong Zhao, Jiaqi Li, Prafulla C. Gokhale, Hong L. Tiv, Aine R. Knott, Margaret K. Wilkens, Kara M. Soroko, Mika Lin, Chiara Ambrogio, Monica Musteanu, Atsuko Ogino, Jihyun Choi, Magda Bahcall, Arrien A. Bertram, Emily S. Chambers, Cloud P. Paweletz, Shripad V. Bhagwat, Jason R. Manro, Ramon V. Tiu, Pasi A. Jänne
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2021) 20 (4): 641–654.
https://doi.org/10.1158/1535-7163.MCT-20-0531
Published: 01 April 2021
View article titled, ERK Inhibitor LY3214996-Based Treatment Strategies for <em>RAS</em>-Driven Lung Cancer
Open the PDF for ERK Inhibitor LY3214996-Based Treatment Strategies for <em>RAS</em>-Driven Lung Cancer in another window
Journal Articles

Combined Targeting of the BRD4–NUT–p300 Axis in NUT Midline Carcinoma by Dual Selective Bromodomain Inhibitor, NEO2734

Chevaun D. Morrison-Smith, Tatiana M. Knox, Ivona Filic, Kara M. Soroko, Benjamin K. Eschle, Margaret K. Wilkens, Prafulla C. Gokhale, Francis Giles, Andrew Griffin, Bill Brown, Geoffrey I. Shapiro, Beth E. Zucconi, Philip A. Cole, Madeleine E. Lemieux, Christopher A. French
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2020) 19 (7): 1406–1414.
https://doi.org/10.1158/1535-7163.MCT-20-0087
Published: 02 July 2020
View article titled, Combined Targeting of the BRD4–NUT–p300 Axis in NUT Midline Carcinoma by Dual Selective Bromodomain Inhibitor, NEO2734
Open the PDF for Combined Targeting of the BRD4–NUT–p300 Axis in NUT Midline Carcinoma by Dual Selective Bromodomain Inhibitor, NEO2734 in another window
Includes: Supplementary data
Journal Articles

Preclinical Characterization of OSI-027, a Potent and Selective Inhibitor of mTORC1 and mTORC2: Distinct from Rapamycin

Shripad V. Bhagwat, Prafulla C. Gokhale, Andrew P. Crew, Andy Cooke, Yan Yao, Christine Mantis, Jennifer Kahler, Jennifer Workman, Mark Bittner, Lorina Dudkin, David M. Epstein, Neil W. Gibson, Robert Wild, Lee D. Arnold, Peter J. Houghton, Jonathan A. Pachter
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (8): 1394–1406.
https://doi.org/10.1158/1535-7163.MCT-10-1099
Published: 08 August 2011
View article titled, Preclinical Characterization of OSI-027, a Potent and Selective Inhibitor of mTORC1 and mTORC2: Distinct from Rapamycin
Open the PDF for Preclinical Characterization of OSI-027, a Potent and Selective Inhibitor of mTORC1 and mTORC2: Distinct from Rapamycin in another window
Includes: Supplementary data
Journal Articles

Compensatory Insulin Receptor (IR) Activation on Inhibition of Insulin-Like Growth Factor-1 Receptor (IGF-1R): Rationale for Cotargeting IGF-1R and IR in Cancer

Elizabeth Buck, Prafulla C. Gokhale, Susan Koujak, Eric Brown, Alexandra Eyzaguirre, Nianjun Tao, Maryland Rosenfeld-Franklin, Lorena Lerner, M. Isabel Chiu, Robert Wild, David Epstein, Jonathan A. Pachter, Mark R. Miglarese
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2010) 9 (10): 2652–2664.
https://doi.org/10.1158/1535-7163.MCT-10-0318
Published: 10 October 2010
View article titled, Compensatory Insulin Receptor (IR) Activation on Inhibition of Insulin-Like Growth Factor-1 Receptor (IGF-1R): Rationale for Cotargeting IGF-1R and IR in Cancer
Open the PDF for Compensatory Insulin Receptor (IR) Activation on Inhibition of Insulin-Like Growth Factor-1 Receptor (IGF-1R): Rationale for Cotargeting IGF-1R and IR in Cancer in another window
Includes: Supplementary data